Key result
Preoperative hemostasis testing has limited clinical utility in patients with liver disease, and abnormal coagulation parameters should not trigger prophylactic blood product transfusion.
Why the study?
Does preoperative hemostasis testing and prophylactic transfusion improve outcomes in patients with liver disease?
Does preoperative hemostasis testing and prophylactic transfusion improve outcomes in patients with liver disease?
Abnormal preoperative hemostasis tests in patients with liver disease should not routinely trigger prophylactic blood product transfusion.
May warrant avoiding test-triggered transfusions in liver disease; leaves open prospective trials for confirmation.
Preoperative hemostasis testing may have limited use in patients with liver disease, and an abnormal platelet count, prothrombin time, activated partial thromboplastin time, and fibrinogen level should not trigger prophylactic transfusion of blood product components.
No takes yet. Share an insight, caveat, or question.
Lisman et al. (2016) studied this question. Preoperative hemostasis testing has limited clinical utility in patients with liver disease, and abnormal coagulation parameters should not trigger prophylactic blood product transfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: